Behandlungsergebnisse bei rezidivierender respiratorischer Papillomatose

Papaioannou, Vasiliki-Anna; Lux, Anke; Voigt-Zimmermann, Susanne; Arens, Christoph

doi:10.1007/s00106-017-0377-1

Cited by 5 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Die Impfung gegen humane Papillomaviren stellt einen effektiven präventiven Ansatz [45], [46], [47]. Vorteil ist die geringe Rate an Nebenwirkungen, weshalb die Impfung als Therapieversuch großzügig indiziert wird.…”

Section: Therapeutische Vakzinierungunclassified

Rezidivierende respiratorische Papillomatose: Aktuelles zu Diagnose und Therapie

Langer¹,

Wittekindt²,

Wolf³

2019

Laryngo-Rhino-Otol

View full text Add to dashboard Cite

ZusammenfassungDie rezidivierende respiratorische Papillomatose (RRP) – ausgelöst durch das humane Papillomavirus (HPV) – ist durch warzenartige Veränderungen der Atemwege gekennzeichnet. Der klinische Verlauf ist variabel, die Diagnosestellung erfolgt nicht selten wesentlich später als der Symptombeginn, insbesondere bei Kindern. Die Behandlung wird individuell festgelegt und umfasst meist Operationen zur Tumorkontrolle und zum Erhalt der Stimmfunktion.

show abstract

Section: Therapeutische Vakzinierungunclassified

Rezidivierende respiratorische Papillomatose: Aktuelles zu Diagnose und Therapie

Langer¹,

Wittekindt²,

Wolf³

2019

Laryngo-Rhino-Otol

View full text Add to dashboard Cite

show abstract

An updated review of the epidemiological factors associated with recurrent respiratory papillomatosis

Welschmeyer

Berke

2021

Laryngoscope Investig Oto

View full text Add to dashboard Cite

Objectives To identify studies evaluating the epidemiology of recurrent respiratory papillomatosis (RRP), including patient demographics, human papillomavirus (HPV) immunology, clinical course, surgical and medical treatments, and psychosocial factors. Methods A systematic literature search through PubMed was performed to identify studies evaluating the epidemiological factors associated with RRP. All studies were screened through a priori selection criteria using the titles and abstracts. Results A total of 208 studies were identified, of which 54 met eligibility criteria and were included in the review. Conclusions RRP is a rare disease most commonly caused by HPV 6 and 11. It is characterized by recurring benign papillomatous lesions in the respiratory tract, particularly the larynx. Existing evidence about disease risk factors is limited but includes both maternal HPV infection and patient smoking and sexual behaviors. Disease management involves a combination of routine surgical and medical treatment. Surgical techniques include CO2‐laser, sharp dissection, coblation, microdebridement, and photoangiolytic laser. Medical treatments which have been found to facilitate disease control off‐label include interferon‐alpha (IFN‐α), indole‐3‐carbinol, acyclovir, bevacizumab, retinoids, and the Gardasil and mumps vaccines. Many patients suffer from additional psychosocial challenges related to their diagnosis. Current disease knowledge remains limited, and more robust controlled trials about risk factors, medical therapies, and surgical options are needed. Level of Evidence 5.

show abstract

Rezidivierende respiratorische Papillomatose: Aktuelles zu Diagnose und Therapie

Langer¹,

Wittekindt²,

Wolf³

2020

Onkologie up2date

View full text Add to dashboard Cite

Behandlungsergebnisse bei rezidivierender respiratorischer Papillomatose

Cited by 5 publications

References 30 publications

Rezidivierende respiratorische Papillomatose: Aktuelles zu Diagnose und Therapie

Rezidivierende respiratorische Papillomatose: Aktuelles zu Diagnose und Therapie

An updated review of the epidemiological factors associated with recurrent respiratory papillomatosis

Rezidivierende respiratorische Papillomatose: Aktuelles zu Diagnose und Therapie

Contact Info

Product

Resources

About